Cargando…

A nomogram model for predicting the risk of checkpoint inhibitor‐related pneumonitis for patients with advanced non‐small‐cell lung cancer

OBJECTIVE: Immunotherapy extensively treats advanced non‐small‐cell lung cancer (NSCLC). Although immunotherapy is generally better tolerated than chemotherapy, it can cause multiple immune‐related adverse events (irAEs) involving multiple organs. Checkpoint inhibitor‐related pneumonitis (CIP) is a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yao, Zhang, Lincheng, Cao, Shuhui, Wang, Yue, Ling, Xuxinyi, Zhou, Yan, Zhong, Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469710/ https://www.ncbi.nlm.nih.gov/pubmed/37409360 http://dx.doi.org/10.1002/cam4.6244

Ejemplares similares

A nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer
por: Cao, Shuhui, et al.
Publicado: (2022)

The genomic characteristics of different progression patterns in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors
por: Li, Jingwen, et al.
Publicado: (2021)

A Novel Therapeutic Target for Small-Cell Lung Cancer: Tumor-Associated Repair-like Schwann Cells
por: Cao, Shuhui, et al.
Publicado: (2022)

Tumor genomics and response to chemotherapy in advanced non-small cell lung cancer with exon 20 insertion epidermal growth factor receptor mutations
por: Wang, Yue, et al.
Publicado: (2020)

Prognostic Implication of the Expression Level of PECAM-1 in Non-small Cell Lung Cancer
por: Cao, Shuhui, et al.
Publicado: (2021)

Clinical value of an electromagnetic navigation system for CT-guided percutaneous lung biopsy of peripheral lung lesions
por: Zhang, Yao, et al.
Publicado: (2021)

Development and Validation of a Radiomics Nomogram Using Computed Tomography for Differentiating Immune Checkpoint Inhibitor-Related Pneumonitis From Radiation Pneumonitis for Patients With Non-Small Cell Lung Cancer
por: Qiu, Qingtao, et al.
Publicado: (2022)

Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review
por: Hao, Yuxuan, et al.
Publicado: (2022)

Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC
por: Reuss, Joshua E., et al.
Publicado: (2021)

Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer
por: Chao, Yencheng, et al.
Publicado: (2022)

Clinical characteristics and therapeutic effects of checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer
por: Pang, Li, et al.
Publicado: (2023)

The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients
por: Zhai, Xiaoyang, et al.
Publicado: (2020)

Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience
por: Altan, Mehmet, et al.
Publicado: (2023)

Chronic immune checkpoint inhibitor pneumonitis
por: Naidoo, Jarushka, et al.
Publicado: (2020)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
por: Wang, Hanping, et al.
Publicado: (2019)

Predictive factors and prognosis of immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer patients
por: Liu, Xiaoyu, et al.
Publicado: (2023)

Simultaneous development of pneumonitis and autoimmune diabetes secondary to immune checkpoint inhibitor treatment with durvalumab in an advanced small cell lung cancer patient: A case report
por: Wen, Yan-Ping, et al.
Publicado: (2022)

Clinical applications of radiomics in non-small cell lung cancer patients with immune checkpoint inhibitor-related pneumonitis
por: Shu, Yang, et al.
Publicado: (2023)

Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis
por: Lin, Xinqing, et al.
Publicado: (2022)

Correction: Chronic immune checkpoint inhibitor pneumonitis
Publicado: (2020)

Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management
por: Zhang, Qin, et al.
Publicado: (2021)

High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non‐small cell lung cancer
por: Tone, Mari, et al.
Publicado: (2019)

Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer
por: Lu, Xiaotong, et al.
Publicado: (2022)

Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer
por: Nishiyama, Osamu, et al.
Publicado: (2021)

Pneumonitis in advanced non-small cell lung cancer: no interaction between immune checkpoint inhibition and radiation therapy
por: Neibart, Shane S., et al.
Publicado: (2023)

Radiation and immune checkpoint inhibitor-mediated pneumonitis risk stratification in patients with locally advanced non-small cell lung cancer: role of functional lung radiomics?
por: Thomas, Hannah M. T., et al.
Publicado: (2022)

Characterization of immunomodulatory factors and cells in bronchoalveolar lavage fluid for immune checkpoint inhibitor-related pneumonitis
por: Wang, Peng-Mei, et al.
Publicado: (2023)

Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease
por: Zeng, Zhu, et al.
Publicado: (2022)

Risk factors for pneumonitis in advanced extrapulmonary cancer patients treated with immune checkpoint inhibitors
por: Uchida, Yasuki, et al.
Publicado: (2022)

Advances in CT features and radiomics of checkpoint inhibitor-related pneumonitis: A short review
por: Huang, Jie, et al.
Publicado: (2023)

Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: a multicenter experience
por: Lin, Xinqing, et al.
Publicado: (2021)

Identification and prediction of immune checkpoint inhibitors-related pneumonitis by machine learning
por: Gong, Li, et al.
Publicado: (2023)

Risk Factors for Refractory Immune Checkpoint Inhibitor-related Pneumonitis in Patients With Lung Cancer
por: Tan, Peixin, et al.
Publicado: (2023)

Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis
por: Chen, Xinru, et al.
Publicado: (2020)

Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis
por: Li, Yanlin, et al.
Publicado: (2023)

Advances in immune checkpoint inhibitors therapy for small cell lung cancer
por: Li, Longhui, et al.
Publicado: (2023)

Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis
por: Huang, Aiben, et al.
Publicado: (2021)

Radiation pneumonitis in patients with non-small-cell lung cancer receiving chemoradiotherapy and an immune checkpoint inhibitor: a retrospective study
por: Jang, Jeong Yun, et al.
Publicado: (2021)

Eosinophil as a biomarker for diagnosis, prediction, and prognosis evaluation of severe checkpoint inhibitor pneumonitis
por: Li, Yanlin, et al.
Publicado: (2022)

Treatment of steroid‐resistant checkpoint inhibitor pneumonitis with pirfenidone: A case report
por: Miao, Kang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6ui5i8co2i8stv9mre95nhfjuv